Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia. (PubMed, Leukemia) - Oct 2, 2026 - "Thereby, loop-mediated upregulation of IGF1R was identified in IDH1-mut AML, corresponding to specific sensitivity to IGF1R inhibitor BMS-754807 as mono- and combination therapy with ivosidenib, while DNMT3A-mut AML exhibited sensitivity to p38/MAPK inhibitor ralimetinib. Our data present a comprehensive map of global 3D-DNA alterations associated with IDH1- and DNMT3A mutations as a basis for further assessment of novel therapeutic strategies for both AML entities."
Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • DNMT3A • IDH1
|
|
Alina Maria Hartmann; Britta Steer; Christoph Röllig; Claudia Dorothea Baldus; David Baden; Kathrin Richter; Kristin Schultz; Lars Fransecky; Lorenz Bastian; Malte Spielmann; Martin Neumann; Miriam Denker; Monika Brüggemann; Nadine Wolgast; Patricia Silva; Simone Lipinski; Sonja Bendig; Sophie Steinhäuser; Theodor Hutter; Thomas Beder; Varun K A Sreenivasan; Verónica Yumiceba
|